<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03788811</url>
  </required_header>
  <id_info>
    <org_study_id>dM/CL-01</org_study_id>
    <nct_id>NCT03788811</nct_id>
  </id_info>
  <brief_title>ERG Components in Schizophrenia and Bipolar Disorder Type I</brief_title>
  <official_title>Assessment of ERG Components to Discriminate Between Schizophrenia and Bipolar Disorder Type I</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>diaMentis Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>diaMentis Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will further assess ERG components obtained with different ERG devices, to be&#xD;
      considered in a prediction model for each diagnosis. The prediction models are diaMentis&#xD;
      proprietary software used as an ERG-based diagnostic test (classified as a Software as&#xD;
      Medical Device, SaMD) to support the diagnosis of schizophrenia and bipolar disorder type I.&#xD;
      They involve the processing and analysis of specific retinal biosignatures (RSPA) with the&#xD;
      support of statistical and mathematical modelling processes e.g. machine learning and&#xD;
      statistical learning.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The technology under development by diaMentis is defined as a Software as a Medical Device&#xD;
      (SaMD); it will be used in combination with an electroretinogram (ERG). This study will be&#xD;
      performed using three different ERG devices, currently marketed and cleared by the health&#xD;
      authorities (Espion, UTAS and RETeval) to support the analytical, scientific and performance&#xD;
      validity of the SaMD.&#xD;
&#xD;
      Anomalies detected by ERG provide an objective measure that may reflect specific underlying&#xD;
      dysfunctions in patients and thus hold promise to confirm relevant biosignatures in&#xD;
      psychiatric disorders. Significant differences between patients with SZ, BPI and control&#xD;
      subjects have been found despite confounding factors; this trial is required to better define&#xD;
      the impact of patient characteristics on ERG features with a potential to refine the&#xD;
      interpretation of results.&#xD;
&#xD;
      This is a multicenter study. Three hundred subjects will be enrolled into three groups: 100&#xD;
      SZ patients, 100 BPI patients and 100 control subjects (healthy volunteers).&#xD;
&#xD;
      The primary objective is to further characterize the ERG components in SZ and BPI patients in&#xD;
      order to develop prediction models that discriminate each pathology.&#xD;
&#xD;
      The secondary objectives are the evaluation of the repeatability and reproducibility of the&#xD;
      analysis of the ERG components in control subjects, the assessment of the reliability of ERG&#xD;
      prediction score for patients following a repeat test, and the evaluation of the impact of&#xD;
      different ERG devices on the data generated and the prediction models.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 5, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Differences in ERG components vs control ERG with full-field ERG stimulation conditions.</measure>
    <time_frame>Three ERG assessments within 6 weeks.</time_frame>
    <description>ERG components are retinal signal features (signal amplitude vs time) in the electrical signal recorded up to 100 msec post stimulation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Differences in ERG components vs control ERG with Photopic Negative Response (PhNR) ERG stimulation conditions.</measure>
    <time_frame>Three ERG assessments within 6 weeks.</time_frame>
    <description>ERG components are retinal signal features (signal amplitude vs time) in the electrical signal recorded up to 250 msec post stimulation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Differences in ERG components vs control ERG with On-Off ERG stimulation conditions.</measure>
    <time_frame>Three ERG assessments within 6 weeks.</time_frame>
    <description>ERG components are retinal signal features (signal amplitude vs time) in the electrical signal recorded up to 300 msec post stimulation.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Bipolar I Disorder</condition>
  <arm_group>
    <arm_group_label>Control subjects</arm_group_label>
    <description>Control subjects who do not have a lifetime diagnosis of SZ, BP, other psychotic disorder, recurrent mood disorder or have not met criteria for a major depression episode in the last 12 months according to DSM-V criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with schizophrenia (SZ)</arm_group_label>
    <description>Patient with a diagnosis of schizophrenia for at least 12 months, that resulted in a diagnosis with a Structured Clinical Interview for DSM-5 (SCID-5-CT).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with bipolar disorder Type I (BP1)</arm_group_label>
    <description>Patient with a diagnosis of bipolar disorder Type 1 for at least 12 months, that resulted in a diagnosis with a Structured Clinical Interview for DSM-5 (SCID-5-CT).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ERG assessment (RSPA)</intervention_name>
    <description>Processing and analysis of retinal signals</description>
    <arm_group_label>Control subjects</arm_group_label>
    <arm_group_label>Patients with bipolar disorder Type I (BP1)</arm_group_label>
    <arm_group_label>Patients with schizophrenia (SZ)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with a likely diagnosis of SZ or BPI for at least 12 months, that resulted in a&#xD;
        diagnosis of SZ or BPI with a Structured Clinical Interview for DSM-5 (SCID-5-CT); and&#xD;
        control subjects who do not have a lifetime diagnosis of SZ, BP, other psychotic disorder,&#xD;
        recurrent mood disorder or have not met criteria for a major depression episode in the last&#xD;
        12 months according to DSM-V criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able to give written informed consent;&#xD;
&#xD;
          -  18 to 50 years old;&#xD;
&#xD;
          -  Patient with a likely diagnosis of SZ or BPI for at least 12 months, that resulted in&#xD;
             a diagnosis of SZ or BPI with a Structured Clinical Interview for DSM-5 (SCID-5-CT);&#xD;
&#xD;
          -  Control subjects who do not have a lifetime diagnosis of SZ, BP, other psychotic&#xD;
             disorder, recurrent mood disorder or have not met criteria for a major depression&#xD;
             episode in the last 12 months according to DSM-V criteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Control subjects taking antipsychotic drugs (other prescription medicines are&#xD;
             allowed);&#xD;
&#xD;
          -  Control subjects with a first-degree relative with SZ, BP, other psychotic disorder or&#xD;
             recurrent major depressive disorder;&#xD;
&#xD;
          -  Patient currently in an acute inpatient unit and not stable (i.e. experiencing an&#xD;
             acute exacerbation of psychosis or mania);&#xD;
&#xD;
          -  Diagnosed dementia, Parkinson's disease, autism or other pervasive developmental&#xD;
             disorders or seizure disorders (such as epilepsy);&#xD;
&#xD;
          -  Substance use disorder within the last 6 months;&#xD;
&#xD;
          -  Any known diagnosis of ophthalmological abnormalities, such as diabetic retinopathy,&#xD;
             glaucoma, change in intraocular pressure, macular degeneration, other retinal&#xD;
             pathologies, congenital color vision deficiencies, strabismus or cataract;&#xD;
&#xD;
          -  Any person contra-indicated for an ERG test, including active corneal or conjunctival&#xD;
             disease (e.g. pink eye or conjunctivitis), infection or a ruptured globe;&#xD;
&#xD;
          -  Subjects in recovery phase following cataract surgery or post LASIK refractive surgery&#xD;
             or trabeculectomy or any surgical/laser intervention, suspected penetrating ocular&#xD;
             injury, ocular prosthesis or severe photophobia;&#xD;
&#xD;
          -  Any person unable to or unwilling to participate in a psychiatric evaluation or ERG&#xD;
             testing, including, in the clinical judgment of the Principal investigator, subjects&#xD;
             with cognitive impairment that compromises their ability to participate meaningfully&#xD;
             in a SCID-5-CT interview.&#xD;
&#xD;
          -  Any subject during the course of the study that is pregnant or intends on becoming&#xD;
             pregnant and/or receives or intends to receive fertility treatments. Subjects becoming&#xD;
             pregnant during study will be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claude Hariton, PhD, DSc</last_name>
    <role>Study Director</role>
    <affiliation>diaMentis Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claude Hariton, PhD, DSc</last_name>
    <phone>418-380-5757</phone>
    <email>chariton@diamentis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Claudia Émond, MSc</last_name>
    <phone>418-380-5757</phone>
    <email>cemond@diamentis.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>McLean Hospital</name>
      <address>
        <city>Belmont</city>
        <state>Massachusetts</state>
        <zip>02478</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Eve Lewandowski, PhD</last_name>
      <phone>617-855-2886</phone>
      <email>klewandowski@mclean.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Kathryn Eve Lewandowski, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers University Behavioral HealthCare</name>
      <address>
        <city>Piscataway</city>
        <state>New Jersey</state>
        <zip>08854</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven M. Silverstein, PhD</last_name>
      <phone>585-275-6742</phone>
      <email>steven_silverstein@urmc.rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Steven M. Silverstein, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre for Addiction and Mental Health (CAMH)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6J 1H4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ofer Agid, MD, PhD</last_name>
      <phone>416-535-8501</phone>
      <phone_ext>34862</phone_ext>
      <email>Ofer.Agid@camh.ca</email>
    </contact>
    <investigator>
      <last_name>Ofer Agid, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire en Santé Mentale de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H1N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valérie Tourjman, MD, PhD</last_name>
      <phone>514-251-4000</phone>
      <phone_ext>3696</phone_ext>
      <email>vtourjman.iusmm@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Valérie Tourjman, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Douglas Mental Health University Institute</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4H 1R3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Lepage, PhD</last_name>
      <phone>514-761-6131</phone>
      <phone_ext>4393</phone_ext>
      <email>martin.lepage@mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Martin Lepage, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Douglas Mental Health University Institute</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4H 1R3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Serge Beaulieu, MD, PhD, FRCP</last_name>
      <phone>514-761-6131</phone>
      <phone_ext>3303</phone_ext>
      <email>serge.beaulieu@mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Serge Beaulieu, MD, PhD, FRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CISSS-CA Hôpital de Saint-Georges</name>
      <address>
        <city>Saint-Georges</city>
        <state>Quebec</state>
        <zip>G5Y 4T8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis Cliche, MD, FRCP</last_name>
      <phone>418-228-2068</phone>
      <email>denis.cliche.med@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Denis Cliche, MD, FRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>December 20, 2018</study_first_submitted>
  <study_first_submitted_qc>December 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 28, 2018</study_first_posted>
  <last_update_submitted>June 20, 2021</last_update_submitted>
  <last_update_submitted_qc>June 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Retinal Signal</keyword>
  <keyword>Schizophrenia</keyword>
  <keyword>Bipolar I Disorder</keyword>
  <keyword>Support to diagnostic</keyword>
  <keyword>ERG</keyword>
  <keyword>Mental Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

